Is LUNG or CARL more profitable?

Pulmonx has a net margin of -55.03% compared to Carlsmed's net margin of -57.42%. Carlsmed's return on equity of -38.06% beat Pulmonx's return on equity. Company Net Margins Return on Equity Return on Assets Pulmonx -55.03% -96.66% -38.32% Carlsmed -57.42% -38.06% -28.96%

Is ELMD or LUNG more profitable?

Electromed has a net margin of 11.34% compared to Pulmonx's net margin of -55.03%. Electromed's return on equity of 15.71% beat Pulmonx's return on equity. Company Net Margins Return on Equity Return on Assets Electromed 11.34% 15.71% 13.37% Pulmonx -55.03% -96.66% -38.32%

Is CV or LUNG more profitable?

Pulmonx has a net margin of -55.03% compared to CapsoVision's net margin of -214.74%. Pulmonx's return on equity of -96.66% beat CapsoVision's return on equity. Company Net Margins Return on Equity Return on Assets CapsoVision -214.74% -177.85% -135.07% Pulmonx -55.03% -96.66% -38.32%

Pulmonx (LUNG) Competitors

$2.26 0.00 (0.00%)

As of 08/21/2026 04:00 PM Eastern

Compare

LUNG vs. CARL, ELMD, SENS, TLSI, and CV

Should you buy Pulmonx stock or one of its competitors? Pulmonx's main competitors and comparable companies include Carlsmed (CARL), Electromed (ELMD), Senseonics Holdings, Inc. Common Stock (SENS), TriSalus Life Sciences (TLSI), and CapsoVision (CV). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Pulmonx compare to Carlsmed?

Pulmonx (NASDAQ:LUNG) and Carlsmed (NASDAQ:CARL) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, analyst recommendations, profitability, dividends, institutional ownership and risk.

91.0% of Pulmonx shares are held by institutional investors. 7.5% of Pulmonx shares are held by insiders. Comparatively, 12.9% of Carlsmed shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Carlsmed has lower revenue, but higher earnings than Pulmonx. Carlsmed is trading at a lower price-to-earnings ratio than Pulmonx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulmonx	$90.50M	1.07	-$54M	-$1.16	N/A
Carlsmed	$50.51M	8.67	-$29.63M	-$1.43	N/A

Pulmonx has a net margin of -55.03% compared to Carlsmed's net margin of -57.42%. Carlsmed's return on equity of -38.06% beat Pulmonx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulmonx	-55.03%	-96.66%	-38.32%
Carlsmed	-57.42%	-38.06%	-28.96%

In the previous week, Carlsmed had 2 more articles in the media than Pulmonx. MarketBeat recorded 2 mentions for Carlsmed and 0 mentions for Pulmonx. Carlsmed's average media sentiment score of 0.51 beat Pulmonx's score of 0.00 indicating that Carlsmed is being referred to more favorably in the news media.

Company	Overall Sentiment
Pulmonx	Neutral
Carlsmed	Positive

Pulmonx currently has a consensus price target of $7.67, suggesting a potential upside of 239.23%. Carlsmed has a consensus price target of $19.25, suggesting a potential upside of 19.94%. Given Pulmonx's higher probable upside, equities analysts plainly believe Pulmonx is more favorable than Carlsmed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulmonx	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Carlsmed	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Carlsmed beats Pulmonx on 8 of the 14 factors compared between the two stocks.

How does Pulmonx compare to Electromed?

Electromed (NYSE:ELMD) and Pulmonx (NASDAQ:LUNG) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, risk, valuation, earnings, institutional ownership, analyst recommendations, profitability and media sentiment.

In the previous week, Electromed's average media sentiment score of 0.00 equaled Pulmonx'saverage media sentiment score.

Company	Overall Sentiment
Electromed	Neutral
Pulmonx	Neutral

Electromed has a net margin of 11.34% compared to Pulmonx's net margin of -55.03%. Electromed's return on equity of 15.71% beat Pulmonx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Electromed	11.34%	15.71%	13.37%
Pulmonx	-55.03%	-96.66%	-38.32%

40.8% of Electromed shares are held by institutional investors. Comparatively, 91.0% of Pulmonx shares are held by institutional investors. 10.5% of Electromed shares are held by company insiders. Comparatively, 7.5% of Pulmonx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Electromed currently has a consensus target price of $37.50, suggesting a potential downside of 4.94%. Pulmonx has a consensus target price of $7.67, suggesting a potential upside of 239.23%. Given Pulmonx's higher possible upside, analysts clearly believe Pulmonx is more favorable than Electromed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Electromed	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Pulmonx	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Electromed has higher earnings, but lower revenue than Pulmonx. Pulmonx is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Electromed	$71.75M	4.55	$5.15M	$1.17	33.72
Pulmonx	$90.50M	1.07	-$54M	-$1.16	N/A

Electromed has a beta of 0.51, meaning that its stock price is 49% less volatile than the broader market. Comparatively, Pulmonx has a beta of 0.28, meaning that its stock price is 72% less volatile than the broader market.

Summary

Electromed beats Pulmonx on 10 of the 13 factors compared between the two stocks.

How does Pulmonx compare to Senseonics Holdings, Inc. Common Stock?

Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) and Pulmonx (NASDAQ:LUNG) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

Senseonics Holdings, Inc. Common Stock has a beta of 1.01, suggesting that its stock price is 1% more volatile than the broader market. Comparatively, Pulmonx has a beta of 0.28, suggesting that its stock price is 72% less volatile than the broader market.

Senseonics Holdings, Inc. Common Stock currently has a consensus target price of $17.20, suggesting a potential upside of 77.14%. Pulmonx has a consensus target price of $7.67, suggesting a potential upside of 239.23%. Given Pulmonx's higher possible upside, analysts plainly believe Pulmonx is more favorable than Senseonics Holdings, Inc. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Senseonics Holdings, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Pulmonx	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Senseonics Holdings, Inc. Common Stock had 3 more articles in the media than Pulmonx. MarketBeat recorded 3 mentions for Senseonics Holdings, Inc. Common Stock and 0 mentions for Pulmonx. Senseonics Holdings, Inc. Common Stock's average media sentiment score of 1.45 beat Pulmonx's score of 0.00 indicating that Senseonics Holdings, Inc. Common Stock is being referred to more favorably in the media.

Company	Overall Sentiment
Senseonics Holdings, Inc. Common Stock	Positive
Pulmonx	Neutral

Pulmonx has higher revenue and earnings than Senseonics Holdings, Inc. Common Stock. Senseonics Holdings, Inc. Common Stock is trading at a lower price-to-earnings ratio than Pulmonx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Senseonics Holdings, Inc. Common Stock	$35.26M	11.51	-$69.11M	-$2.23	N/A
Pulmonx	$90.50M	1.07	-$54M	-$1.16	N/A

12.4% of Senseonics Holdings, Inc. Common Stock shares are held by institutional investors. Comparatively, 91.0% of Pulmonx shares are held by institutional investors. 4.7% of Senseonics Holdings, Inc. Common Stock shares are held by insiders. Comparatively, 7.5% of Pulmonx shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Pulmonx has a net margin of -55.03% compared to Senseonics Holdings, Inc. Common Stock's net margin of -225.09%. Pulmonx's return on equity of -96.66% beat Senseonics Holdings, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Senseonics Holdings, Inc. Common Stock	-225.09%	-165.80%	-80.14%
Pulmonx	-55.03%	-96.66%	-38.32%

Summary

Pulmonx beats Senseonics Holdings, Inc. Common Stock on 10 of the 15 factors compared between the two stocks.

How does Pulmonx compare to TriSalus Life Sciences?

Pulmonx (NASDAQ:LUNG) and TriSalus Life Sciences (NASDAQ:TLSI) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, dividends, analyst recommendations, institutional ownership and earnings.

In the previous week, TriSalus Life Sciences had 3 more articles in the media than Pulmonx. MarketBeat recorded 3 mentions for TriSalus Life Sciences and 0 mentions for Pulmonx. TriSalus Life Sciences' average media sentiment score of 0.62 beat Pulmonx's score of 0.00 indicating that TriSalus Life Sciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Pulmonx	Neutral
TriSalus Life Sciences	Positive

Pulmonx has a net margin of -55.03% compared to TriSalus Life Sciences' net margin of -62.59%. TriSalus Life Sciences' return on equity of 0.00% beat Pulmonx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulmonx	-55.03%	-96.66%	-38.32%
TriSalus Life Sciences	-62.59%	N/A	-64.47%

Pulmonx presently has a consensus target price of $7.67, suggesting a potential upside of 239.23%. TriSalus Life Sciences has a consensus target price of $7.50, suggesting a potential upside of 42.31%. Given Pulmonx's stronger consensus rating and higher probable upside, research analysts plainly believe Pulmonx is more favorable than TriSalus Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulmonx	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
TriSalus Life Sciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

TriSalus Life Sciences has lower revenue, but higher earnings than Pulmonx. TriSalus Life Sciences is trading at a lower price-to-earnings ratio than Pulmonx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulmonx	$90.50M	1.07	-$54M	-$1.16	N/A
TriSalus Life Sciences	$45.15M	7.19	-$39.23M	-$1.30	N/A

Pulmonx has a beta of 0.28, suggesting that its stock price is 72% less volatile than the broader market. Comparatively, TriSalus Life Sciences has a beta of 0.43, suggesting that its stock price is 57% less volatile than the broader market.

91.0% of Pulmonx shares are held by institutional investors. Comparatively, 2.6% of TriSalus Life Sciences shares are held by institutional investors. 7.5% of Pulmonx shares are held by company insiders. Comparatively, 16.3% of TriSalus Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Pulmonx beats TriSalus Life Sciences on 9 of the 16 factors compared between the two stocks.

How does Pulmonx compare to CapsoVision?

CapsoVision (NASDAQ:CV) and Pulmonx (NASDAQ:LUNG) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.

CapsoVision presently has a consensus target price of $8.50, suggesting a potential upside of 41.20%. Pulmonx has a consensus target price of $7.67, suggesting a potential upside of 239.23%. Given Pulmonx's higher possible upside, analysts plainly believe Pulmonx is more favorable than CapsoVision.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CapsoVision	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Pulmonx	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

91.0% of Pulmonx shares are owned by institutional investors. 2.3% of CapsoVision shares are owned by insiders. Comparatively, 7.5% of Pulmonx shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

CapsoVision has higher earnings, but lower revenue than Pulmonx. CapsoVision is trading at a lower price-to-earnings ratio than Pulmonx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CapsoVision	$13.89M	21.69	-$25.32M	-$0.47	N/A
Pulmonx	$90.50M	1.07	-$54M	-$1.16	N/A

In the previous week, CapsoVision's average media sentiment score of 0.00 equaled Pulmonx'saverage media sentiment score.

Company	Overall Sentiment
CapsoVision	Neutral
Pulmonx	Neutral

Pulmonx has a net margin of -55.03% compared to CapsoVision's net margin of -214.74%. Pulmonx's return on equity of -96.66% beat CapsoVision's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CapsoVision	-214.74%	-177.85%	-135.07%
Pulmonx	-55.03%	-96.66%	-38.32%

Summary

Pulmonx beats CapsoVision on 9 of the 13 factors compared between the two stocks.

Get Pulmonx News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LUNG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LUNG vs. The Competition

Export

Metric	Pulmonx	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$97.07M	$5.88B	$7.32B	$12.82B
Dividend Yield	N/A	1.75%	2.54%	10.79%
P/E Ratio	-1.95	26.54	272.91	24.33
Price / Sales	1.07	70.83	603.26	75.73
Price / Cash	N/A	33.71	29.03	36.90
Price / Book	1.73	6.22	11.33	6.42
Net Income	-$54M	$149.90M	$3.47B	$348.89M
7 Day Performance	1.35%	1.14%	2.21%	0.51%
1 Month Performance	93.16%	9.19%	7.64%	4.84%
1 Year Performance	33.73%	8.06%	25.18%	17.04%

Pulmonx Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LUNG Pulmonx	1.9112 of 5 stars	$2.26 flat	$7.67 +239.2%	+33.7%	$97.07M	$90.50M	N/A	250
CARL Carlsmed	1.281 of 5 stars	$13.91 +0.9%	$19.25 +38.4%	N/A	$380.51M	$50.51M	N/A	100	Gap Up
ELMD Electromed	0.659 of 5 stars	$40.36 +0.3%	$37.50 -7.1%	+94.6%	$333.35M	$71.75M	53.68	160
SENS Senseonics Holdings, Inc. Common Stock	3.4764 of 5 stars	$7.96 -0.9%	$17.20 +116.1%	N/A	$332.33M	$48.55M	N/A	90	Positive News Gap Down
TLSI TriSalus Life Sciences	1.3744 of 5 stars	$5.39 +2.3%	$7.50 +39.1%	+4.4%	$318.31M	$45.15M	N/A	106	News Coverage Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LUNG) was last updated on 8/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pulmonx (LUNG) Competitors